Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ASCO: Trial compares common adjuvant treatments for pancreatic cancer

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 18 Jun 2009

Views: 13237

Rating:

Save

Dr. John Neoptolemos - University of Liverpool, Liverpool, UK

ASCO press conference: A phase III trial comparing the adjuvant treatments most commonly used for pancreatic cancer in the United States and Europe (gemcitabine and 5- FU/FA, respectively) found that there is no difference in survival between the two regimens, though gemcitabine was associated with fewer side effects.

Categories:
Colorectal & gastro

Related Videos

Post-diagnosis diet, nutrition and cancer prognosis

Dr Doris Chan - Imperial College London, London, UK

Post-diagnosis diet, nutrition and cancer prognosis ( Dr Doris Chan - Imperial College London, London, UK )

WCI's role in the prevention of tobacco related cancer among Beedi rolling...

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )

Alternative livelihood training programme for rural women who are employed in...

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )

Selecting patients wisely for neoadjuvant therapy in HPB cancers

Dr Shailesh V. Shrikhande - Tata Memorial Hospital, Mumbai, India

Selecting patients wisely for neoadjuvant therapy in HPB cancers ( Dr Shailesh V. Shrikhande - Tata Memorial Hospital, Mumbai, India )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Mutational-based treatment approach may significantly improve outcomes in...

Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours ( Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Assessment of suicide risk in cancer patients

Prof Sujit Sarkhel - SSKM Hospital, Kolkata, India

Assessment of suicide risk in cancer patients ( Prof Sujit Sarkhel - SSKM Hospital, Kolkata, India )

Cancer journeys: Research from India

Ms. Soumita Ghose - Tata Medical Center, Kolkata

Cancer journeys: Research from India ( Ms. Soumita Ghose - Tata Medical Center, Kolkata )

More from ecancer